制药商计划2026年提高350+美国药物的价格,平均4%,但因《医疗保险计划》谈判而有所削减。 Drugmakers plan 2026 price hikes on 350+ U.S. drugs, averaging 4%, with some cuts due to Medicare negotiations.

毒品制造者计划提高美国2026年至少350种品牌药品的价格, 包括疫苗和癌症治疗, Drugmakers plan to raise prices on at least 350 branded drugs in the U.S. for 2026, including vaccines and cancer treatments, with a median increase of about 4%, up from over 250 drugs last year. 包括贾迪安斯(Jardianse)在内的约九种药物, 将因医疗计划谈判而减价约超过40%, The hikes exclude rebates and discounts, while about nine drugs, including Jardiance, will see price cuts, some exceeding 40%, due to Medicare negotiations. Pfizer、GSK等都提到创新与成本不断上涨, 有些由医院管理的药品出现大幅增长。 Pfizer, GSK, and others cite innovation and rising costs, with some hospital-administered drugs seeing steep increases. 特朗普政府与14家公司达成了新的价格交易,为医疗补助和付现金的病人提供折扣,但专家说,影响有限。 The Trump administration secured new pricing deals with 14 companies, offering discounts for Medicaid and cash-paying patients, but experts say the impact is limited. 2025年12月,CMS启动了两个试点方案,使美国药物价格与国际基准接轨,如果价格超过19个经合组织国家的价格,则要求退款,2026年2月将发表公开评论。 CMS launched two pilot programs in December 2025 to align U.S. drug prices with international benchmarks, requiring rebates if prices exceed those in 19 OECD countries, with public comments due in February 2026.